SCHEMBL660365

SCHEMBL660365

COc1ccc(C=O)cc1OC(C)C

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.72
TSHR P16473 1/20 0.72
FDPS P14324 1/20 0.57
AOX1 Q06278 1/20 0.56
TRIM24 O15164 1/20 0.56
HPGD P15428 1/20 0.56
ALDH5A1 P51649 1/20 0.56
ABAT P80404 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
TRIM33 Q9UPN9 1/20 0.56
PDE4B Q07343 2/20 0.56
TTR P02766 1/20 0.53
PDE4A P27815 1/20 0.52
PDE4C Q08493 1/20 0.52
PDE4D Q08499 1/20 0.52
ALDH1A3 P47895 2/20 0.52
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31009671 1.00 ALDH1A1 (0.72) ALDH1A1TSHRFDPSAOX1TRIM24
SCHEMBL1159006 0.93 ALDH1A1 (0.72) ALDH1A1TSHRFDPSAOX1TRIM24
SCHEMBL1713698 0.91 ALDH1A1 (0.57) ALDH1A1TSHRFDPSAOX1TRIM24
SCHEMBL11682824 0.86 ALDH1A1 (0.68) ALDH1A1TSHRFDPSAOX1TRIM24
3,4-Dimethoxybenzaldehyde SCHEMBL25202 0.85 ALDH1A1 (1.00) ALDH1A1TSHRFDPSAOX1TRIM24
3,4-Dimethoxybenzaldehyde SCHEMBL1330962 0.85 ALDH1A1 (1.00) ALDH1A1TSHRFDPSAOX1TRIM24
3,4-Dimethoxybenzaldehyde SCHEMBL29364994 0.85 ALDH1A1 (1.00) ALDH1A1TSHRFDPSAOX1TRIM24
3,4-Dimethoxybenzaldehyde SCHEMBL5308959 0.85 ALDH1A1 (1.00) ALDH1A1TSHRFDPSAOX1TRIM24
SCHEMBL1966450 0.84 ALDH1A1 (0.70) ALDH1A1TSHRFDPSAOX1TRIM24
SCHEMBL2393473 0.83 ALDH1A1 (0.64) ALDH1A1TSHRFDPSAOX1TRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3122847-A1 PERFUME SYSTEMS The Procter & Gamble Company (US) 2017-02-01 EP claimed
US-20160289593-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2016-10-06 US claimed
US-20150275132-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY 2015-10-01 US claimed
WO-2015148743-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2015-10-01 WO claimed
EP-0709361-B1 Process for the preparation of isovanilline RHODIA CHIMIE SA (FR) 1999-02-03 EP claimed
US-5786516-A Process for the preparation of isovanillin RHONE-POULENC CHIMIE (FR) 1998-07-28 US claimed
US-5648552-A Process for the preparation of isovanillin RHONE-POULENC CHIMIE (FR) 1997-07-15 US claimed
EP-0709361-A1 Process for the preparation of isovanilline RHONE-POULENC CHIMIE (FR) 1996-05-01 EP claimed
CN-120136683-A Catechol ether compound, pharmaceutical composition and application thereof 中国药科大学 2025-06-13 CN disclosed
WO-2024175086-A1 ARYL TRICYCLIC STING AGONIST AND USE THEREOF 深圳真实生物医药科技有限公司 2024-08-29 WO disclosed
EP-3521409-A2 PERFUME SYSTEMS The Procter & Gamble Company (US) 2019-08-07 EP disclosed
US-20160289593-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2016-10-06 US disclosed
US-20160289593-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2016-10-06 US disclosed
CN-104262229-B Preparation method of 2-phenyl substituted-3-benzoyl substituted indole 广东颐正达医药科技有限公司 2016-10-05 CN disclosed
US-5648552-A Process for the preparation of isovanillin RHONE-POULENC CHIMIE (FR) 1997-07-15 US disclosed
EP-0741707-A1 SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS RHONE-POULENC RORER LIMITED (GB) 1996-11-13 EP disclosed
EP-0709361-A1 Process for the preparation of isovanilline RHONE-POULENC CHIMIE (FR) 1996-05-01 EP disclosed
WO-1995020578-A1 SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS RHONE-POULENC RORER LIMITED (GB) 1995-08-03 WO disclosed
EP-0652868-A1 INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF RHONE-POULENC RORER LIMITED (GB) 1995-05-17 EP disclosed
WO-1994002465-A1 INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF RHONE-POULENC RORER LIMITED (GB) 1994-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160289593-A1 PERFUME SYSTEMS TRPA1, PORCN, PLIN5 ALDH1A1 1292/4885TSHR 4787/4885FDPS 194/4885
US-20150275132-A1 PERFUME SYSTEMS TRPA1, PORCN, PLIN5 ALDH1A1 1292/4885TSHR 4787/4885FDPS 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.